Table 2.
Univariate associations of tenofovir monoester, tenofovir and clinical covariates with tenofovir diphosphate concentrations in PBMC and DBS
| Variable | TFV-DP in PBMC |
TFV-DP in DBSa |
|||||
|---|---|---|---|---|---|---|---|
| change in TFV-DP | 95% CI | P valueb | change in TFV-DP | 95% CI | P valueb | ||
| Visit (2 versus 1) | −5.0% | −24.7% to 20.0% | 0.66 | 95.1% | 59.2%–139.0% | <0.0001 | |
| Randomization sequence | 5.1% | −23.8% to 44.9% | 0.75 | 25.0% | −11.0% to 75.6% | 0.19 | |
| Formulation (encapsulated versus not) | −10.0% | −28.5% to 13.1% | 0.35 | −4.8% | −22.7% to 17.2% | 0.63 | |
| Sex (female versus male) | −9.3% | −34.1% to 24.9% | 0.53 | −5.9% | −33.9% to 33.9% | 0.73 | |
| BMI (kg/m2) | −2.2% | −6.0% to 1.7% | 0.25 | −1.0% | −5.3% to 3.5% | 0.63 | |
| eGFR (mL/min/1.73 m2) | 0.1% | −0.6% to 0.8% | 0.84 | −0.0% | −0.8% to 0.7% | 0.97 | |
| Tenofovir monoester AUC0–∞ (per 10 ng·h/mL)c | 3.8% | 0.8%–6.8% | 0.015 | 4.3% | 1.5%–7.2% | 0.005 | |
| Tenofovir AUC0–∞ (per 10 ng·h/mL)c | 0.2% | −0.1% to 0.5% | 0.11 | 0.0% | −0.3% to 0.3% | >0.99 | |
TFV-DP, tenofovir diphosphate.
a
Reported point estimates for TFV-DP in DBS were controlled for study visit.
b
P values <0.05 are shown in bold.
c
Percentage changes reported per 10 ng·h/mL increase in tenofovir monoester or tenofovir.